The United State Food and Drug Administration (USFDA) has completed inspection at Caplin Point Laboratories’ Sterile Injectable site (CP-IV) at Gummidipoondi between October 21 - 28, 2016. There were only two observations.
The company believes these to be of minor in nature and the corrective and preventive actions for these observations will be presented to the USFDA within the next 15 days. The observations made were not related to data integrity.
Caplin Point Laboratories is engaged mainly in manufacturing a wide range of Ointments, Creams and other External application preparations in addition to the regular segments of pharmaceutical formulations.
